CoChat

Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis

Open access
Guery, Benoît P., Arendrup, Maiken C., Auzinger, Georg, Azoulay, Élie, Borges Sá, Márcio, Johnson, Elizabeth M., Müller, Eckhard, Putensen, Christian, Rotstein, Coleman, Sganga, Gabriele, Venditti, Mario, Zaragoza Crespo, Rafael, Kullberg, Bart Jan · 2009 · Intensive Care Medicine

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index; 7 of the 73 sources its claims cite were checked for support.

Abstract

BACKGROUND: Invasive candidiasis and candidemia are frequently encountered in the nosocomial setting, particularly in the intensive care unit (ICU). OBJECTIVES AND METHODS: To review the current management of invasive candidiasis and candidemia in non-neutropenic adult ICU patients based on a review of the literature and a European expert panel discussion. RESULTS AND CONCLUSIONS: Candida albicans remains the most frequently isolated fungal species followed by C. glabrata. The diagnosis of invasive candidiasis involves both clinical and laboratory parameters, but neither of these are specific. One of the main features in diagnosis is the evaluation of risk factor for infection which will identify patients in need of pre-emptive or empiric treatment. Clinical scores were built from those risk factors. Among laboratory diagnosis, a positive blood culture from a normally sterile site provides positive evidence. Surrogate markers have also been proposed like 1,3 beta-D: glucan level, mannans, or PCR testing. Invasive candidiasis and candidemia is a growing concern in the ICU, apart from cases with positive blood cultures or fluid/tissue biopsy, diagnosis is neither sensitive nor specific. The diagnosis remains difficult and is usually based on the evaluation of risk factors.

Overview

CoChat Summary

TL;DR

This narrative review summarizes the epidemiology and diagnosis of invasive candidiasis and candidemia in adult non-neutropenic ICU patients, emphasizing high attributable mortality and persistent diagnostic difficulty. It reports that Candida spp. are common ICU bloodstream pathogens, C. albicans remains predominant although non-albicans species are increasingly reported, and diagnosis relies on risk factors, colonization indices, cultures, and non-culture markers with imperfect accuracy.

Key findings

  • Candida spp. account for 6–11% of positive nosocomial bloodstream infections; in a US surveillance study, 4.6 bloodstream infections per 10,000 admissions and 9% of all bloodstream infections. ICU candidemia was 10.1% of bloodstream infections versus 7.9% on general wards, and one study reported 15.8/10,000 patient-days in ICUs versus 0.15/10,000 on medical wards and 0.69/10,000 on surgical wards.
  • Attributable mortality of candidiasis was estimated at 49% in 108 matched pairs, with crude mortality 61% in case patients versus 12% in controls; a systematic review of seven matched cohort and case-control studies reported attributable mortality ranging from 5 to 71%. Invasive candidiasis and candidemia were associated with increased ICU and hospital stay of 12.7 and 15.5 days, respectively.
  • C. albicans remained the main pathogen overall, but non-albicans species were increasingly reported. In an Italian ICU study of 182 candidemia episodes, 40% were C. albicans, 23% C. parapsilosis, 15% C. glabrata, 9% C. tropicalis, and 13% other species; in a Canadian 1-day point-prevalence study of 409 isolates, C. albicans accounted for 72% and C. glabrata 16%, with only 4% resistant to fluconazole and/or itraconazole.
  • Diagnosis is challenging: clinical manifestations are non-specific, blood cultures are often positive late, and about 50% of blood culture samples may be inadequate (<20 mL). Reported test performance included beta-D-glucan sensitivity 69.9% and specificity 87.1%; combined mannan/antimannan sensitivity 80% and specificity 93%; and a PCR assay sensitivity 90.9% and specificity 100%. The Pittet colonization index threshold of 0.5 and a corrected index were associated with 100% sensitivity and specificity in a 29-patient study; the Leon Candida score cut-off of 2.5 had sensitivity 81% and specificity 74%.

Methods

  • Narrative review of the international literature on management of invasive candidiasis and candidemia in adult non-neutropenic ICU patients, focused here on epidemiology and diagnosis.
  • No primary patient cohort, systematic search strategy, or meta-analysis is described; the paper synthesizes findings from cited epidemiologic, risk-factor, prediction-rule, colonization-index, and laboratory-diagnostic studies.
  • Main analysis is descriptive, covering incidence and mortality, Candida species distribution, risk factors, clinical prediction rules, colonization indices, and laboratory markers including beta-D-glucan, mannan/antimannan, germ tube antibody, and PCR.

Limitations

  • The paper states that diagnosis is neither sensitive nor specific apart from positive blood cultures or fluid/tissue biopsy, and that there is a clear need for more specific diagnostic markers. It also states that uncertainty exists around the relative mortality of different Candida species, requiring well-controlled studies, and that the influence of azole prophylaxis on Candida epidemiology has not been clearly elucidated.
  • The paper notes limitations of specific cited evidence, including that one prediction study involved only 19 patients with candidemia, that the Pittet colonization-index study evaluated 29 patients, that PCR results need further evaluation, and that beta-D-glucan requires validation in the appropriate ICU setting before routine use.
  • Evident from the text: as a narrative review without a described systematic search or formal quality assessment, the reported incidence, species distribution, and mortality estimates vary widely across heterogeneous, often small, retrospective, or single-center studies.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00134-008-1338-7

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

6 Valid · 0 Not valid · 56 Not checked · 9 Own results and interpretations

15 more claims

Create a free account to see all 71 claims and to verify the 66 references still open.

See all claims — free account
  • It may state two separate claims as one. 41
  • Probably not a substantial claim. 18
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 57 references

Cited by

See all 176

Metadata

Authors
Guery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., Venditti, M., Zaragoza Crespo, R., & Kullberg, B. J.
Affiliations
  • Statens Serum Institut (DK)
  • King's College Hospital (GB)
  • Hôpital Saint-Louis (FR)
  • University Hospitals of the Ruhr-University of Bochum (DE)
  • University of Bonn (DE)
  • University Health Network (CA)
  • Università Cattolica del Sacro Cuore (IT)
  • Sapienza University of Rome (IT)
  • Radboud University Nijmegen (NL)
Corresponding author
Kullberg, Bart Jan
Venue
Intensive Care Medicine
Published
2008-10-30
Volume
35
Issue
1
Pages
55-62
ISSN
  • 0342-4642 (ISSN-L)
  • 1432-1238
OpenAlex
W2012383276
Cited by
173
References
58
Citations by year
2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 4 · 2017: 11 · 2016: 15 · 2015: 17 · 2014: 18 · 2013: 14 · 2012: 11
FWCI
1.93
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Intensive Care Medicine (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nc)
  • Hispana (submittedVersion, cc-by-nc)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
  • INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
  • Pfizer
  • Sanofi
  • Gilead Sciences
  • Fresenius Medical Care North America
  • Astellas Pharma
  • Novartis Pharma
  • Bayer Vital
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
Keywords
invasive candidiasis, candidemia, non-neutropenic patients, intensive care unit, Candida albicans, Candida glabrata, nosocomial fungal infections, risk factors, clinical scoring systems, blood culture, β-1,3-glucan, mannan, PCR detection, antifungal therapy, epidemiology
MeSH terms
Candidiasis, Cross Infection, Europe, Humans, Intensive Care Units, Turkey, Biomarkers, Prevalence, Fungemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. https://app.cochat.ai/papers/10.1007/s00134-008-1338-7
The paper
Guery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., Venditti, M., Zaragoza Crespo, R., & Kullberg, B. J. (2009). Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Medicine. https://doi.org/10.1007/s00134-008-1338-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.